Axomadol

Axomadol

Systematic (IUPAC) name
(1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
Clinical data
Legal status	Investigational New Drug
Identifiers
CAS Number	187219-95-0 187219-99-4
ATC code	None
PubChem	CID 10221318
ChemSpider	8396810
Chemical data
Formula	C16H25NO3
Molar mass	279.375 g/mol
SMILES O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C
InChI InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1 Key:LQJLLAOISDVBJM-FMKPAKJESA-N

Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic of the benzenoid class which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic, moderate to severe lower back pain and arthrosis.^[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.^[3]

See also

• Tramadol

References

1. Chadds Ford (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
2. US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH 
3. Chadds Ford (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.